Emeryville, CA, United States

Eureka Therapeutics

eurekainc.com
Emeryville, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Sloan Kettering Cancer Center and Eureka Therapeutics | Date: 2016-11-30

The present invention provides antigen binding proteins that specifically bind to Wilms tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.


EMERYVILLE, Calif. & DUARTE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics Inc., a biotechnology company focused on developing novel T-cell immunotherapies for the treatment of solid tumors, and City of Hope, a world-renowned independent research and cancer and diabetes treatment center, announced today that they have reached agreement to conduct an open-label, dose-escalating Phase 1 clinical trial of ET1402L1-CAR, a potential CAR-T therapy for the treatment of hepatocellular carcinoma, the predominant type of liver cancer. ET1402L1 is a human antibody, identified from Eureka’s proprietary E-ALPHA™ phage library, which selectively targets liver cancer cells overexpressing alpha-fetoprotein (AFP). “The clinical trial agreement represents an important milestone for Eureka, as it provides a pathway for treating patients with liver cancer, and it supports our business objectives to develop ET1402L1-CAR in areas of significant unmet medical need,” said Cheng Liu, Ph.D., President and Chief Executive Officer of Eureka Therapeutics. “This is a significant step in demonstrating that CAR-T cell therapy can be successfully used to target a major histocompatibility complex (MHC) presented antigen in solid tumors.” Intracellular antigens, which account for the most tumor-specific antigens, are inaccessible by conventional CAR-T therapy. Such antigens which include AFP, however, are processed into peptides and presented by the class I MHC on the surface of tumor cells. A 2017 study (DOI: 10.1158/1078-0432.CCR-16-1203), published by Eureka and City of Hope in Clinical Cancer Research, showed that ET1402L1-CAR T cells can recognize the AFP-MHC complex and launch a potent anti-tumor response, offering a promising new avenue for T cell therapy against solid malignancies. "We are pleased to be working with Eureka Therapeutics on this unique approach to treating liver cancer with CAR-T therapy," said principal investigator Yuman Fong, M.D., The Sangiacomo Family Chair in Surgical Oncology and chair and professor of the Department of Surgery at City of Hope. "CAR-T therapy has shown remarkable success with liquid tumors. However, the lack of cancer specific cell surface antigens has limited the use of CAR-T therapy to other cancers. The results of this study could have a wide range of applications in other difficult-to-treat solid cancers such as lung and prostate cancer, which have few cell surface markers that are tumor-specific.” “City of Hope has accepted the challenge to bring leading-edge treatments to patients with liver cancer,” said investigator Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation and director of City of Hope’s T Cell Immunotherapy Research Laboratory. “We are optimistic that CAR-T therapy can be an important component in treating patients with solid tumors, including liver cancer.” The Phase 1 clinical trial will be led by Fong and Forman. Other collaborating investigators include Christine Brown, Ph.D., Heritage Provider Network Professor in Immunotherapy, John Kessler, M.D., John Park, M.D., Ph.D., Saul Priceman Ph.D., Shirong Wang, M.D., M.P.H., and Susanne Warner, M.D., all of City of Hope in Duarte, California. Liver cancer is the fifth most prevalent and third most lethal cancer worldwide, with incidence rates on the rise and limited treatment options. Hepatocellular carcinoma is the predominant type of liver cancer, affecting over 700,000 people each year worldwide. Alpha-fetoprotein (AFP) is overexpressed, specifically in liver cancer, making it an ideal target for chimeric antigen receptor (CAR) T cell immunotherapy. However, AFP is intracellularly expressed and secreted, and therefore, not targetable by conventional antibody-based therapies. Eureka Therapeutics Inc. is a privately held biotechnology company, headquartered in the San Francisco Bay area, focused on developing first-in-class T cell immunotherapies for hematological malignancies and solid tumors. Its core technology platforms center around the discovery and engineering of fully human antibodies against intracellular targets via the MHCI complex. The company is developing a pipeline of novel cancer therapeutics targeting intracellular oncogenes. For more information, visit the company's website at www.eurekainc.com. City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 48 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.


Dublin, May 09, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global CAR T Cell Therapy Market & Clinical Trials Insight 2022" report to their offering. Global CAR T Cell Therapy Market & Clinical Trials Insight 2022 report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials. In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex. The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. The first commercial application of CAR T Cell based therapy for the treatment of Mantle- Non-Hodgkin's lymphoma is expected to be available from 2020. The anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) is developed by KITE Pharma in collaboration with National Cancer Institute. Currently this therapy is in preregistration phase. In future, the advancement of CAR T Cell therapy will be largely driven by academia and will require the support for the expensive early phase clinical trials which promise to cover the way for a new form of targeted, exportable immunotherapy for cancer patient. The manufacturing of CD19 CAR T cell therapy CTL019 is in a way which will modernize the process of using the therapy globally. The anticipation of regulatory and manufacturing issues before they arise and proactively addressing the concerns helps to accelerate the process of bringing this promising therapeutic approach to more patients in future. Global CAR T Cell Therapy Market & Clinical Trials Insight 2022 report highlights: - CAR T Cell Therapies Delivery Pipeline & Mechanism of Action - Global CAR T Cell Therapy Clinical Trials for Cancer Treatment - Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase - Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies - CAR T Cell Therapies in Highest Phase: Preregistration - Majority of CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies - Global Market Scenario of CAR T Cell Therapy - Global CAR T Cell Therapy Market Future Prospects Key Topics Covered: 1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology 1.1 Overview 1.2 History & Development of CAR-T Technology 2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design 2.1 Structure of CAR T Cell 2.2 1nd Generation Chimeric Antigen Receptor 2.3 2nd & 3nd Generation CAR T Cell 3. Principle of Chimeric Antigen Receptor Design 3.1 CAR Modified T Cells: Targeting 3.2 CAR Modified T Cell: Signaling 4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action 4.1 Process of CAR T Cell Therapy 4.2 Mechanism of Action 5. Approaches to Improve the CAR T Cell Therapy 5.1 Introduction 5.2 Targeting the Tumor Stroma with CAR T Cells 5.3 Targeting the Cytokine Networks 5.4 Combination Strategies for CAR T Cells 5.5 Targeting the Immune Checkpoints 6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment 6.1 Acute Lymphoblastic Leukemia 6.2 Multiple Myeloma 6.3 Brain Tumors 6.4 Lymphoma 6.5 Solid Tumors 7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase 7.1 Research 7.2 Preclinical 7.3 Clinical 7.4 Phase-I 7.5 Phase-I/II 7.6 Phase-II 7.7 Preregistration 8. Global Market Scenario of CAR T Cell Therapy 8.1 Overview 8.2 Estimated Price Analysis of CAR T Cell Therapy 9. Global Market Size of CAR T Cell Therapy 9.1 Market Share of Cancer Immunotherapy by its Technology 9.2 CAR T Cell Therapy Market Value 10. Global CAR T Cell Therapy Market Dynamics 10.1 Favorable Parameters 10.2 Challenges 11. Global CAR T Cell Therapy Market Future Prospects 12. Competitive Landscape 12.1 Autolus 12.2 Bellicum 12.3 Bluebird 12.4 Celgene 12.5 Cellectis 12.6 Celyad 12.7 Eureka Therapeutics 12.8 Fortress Biotech 12.9 Immune Therapeutics 12.10 Juno Therapeutics 12.11 Kite Pharma 12.12 Novartis 12.13 Sorrento therapeutics 12.14 TILT Biotherapeutics 12.15 Ziopharm For more information about this report visit http://www.researchandmarkets.com/research/6tj28w/global_car_t_cell


Dublin, May 09, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global CAR T Cell Therapy Market & Clinical Trials Insight 2022" report to their offering. Global CAR T Cell Therapy Market & Clinical Trials Insight 2022 report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials. In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex. The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. The first commercial application of CAR T Cell based therapy for the treatment of Mantle- Non-Hodgkin's lymphoma is expected to be available from 2020. The anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) is developed by KITE Pharma in collaboration with National Cancer Institute. Currently this therapy is in preregistration phase. In future, the advancement of CAR T Cell therapy will be largely driven by academia and will require the support for the expensive early phase clinical trials which promise to cover the way for a new form of targeted, exportable immunotherapy for cancer patient. The manufacturing of CD19 CAR T cell therapy CTL019 is in a way which will modernize the process of using the therapy globally. The anticipation of regulatory and manufacturing issues before they arise and proactively addressing the concerns helps to accelerate the process of bringing this promising therapeutic approach to more patients in future. Global CAR T Cell Therapy Market & Clinical Trials Insight 2022 report highlights: - CAR T Cell Therapies Delivery Pipeline & Mechanism of Action - Global CAR T Cell Therapy Clinical Trials for Cancer Treatment - Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase - Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies - CAR T Cell Therapies in Highest Phase: Preregistration - Majority of CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies - Global Market Scenario of CAR T Cell Therapy - Global CAR T Cell Therapy Market Future Prospects Key Topics Covered: 1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology 1.1 Overview 1.2 History & Development of CAR-T Technology 2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design 2.1 Structure of CAR T Cell 2.2 1nd Generation Chimeric Antigen Receptor 2.3 2nd & 3nd Generation CAR T Cell 3. Principle of Chimeric Antigen Receptor Design 3.1 CAR Modified T Cells: Targeting 3.2 CAR Modified T Cell: Signaling 4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action 4.1 Process of CAR T Cell Therapy 4.2 Mechanism of Action 5. Approaches to Improve the CAR T Cell Therapy 5.1 Introduction 5.2 Targeting the Tumor Stroma with CAR T Cells 5.3 Targeting the Cytokine Networks 5.4 Combination Strategies for CAR T Cells 5.5 Targeting the Immune Checkpoints 6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment 6.1 Acute Lymphoblastic Leukemia 6.2 Multiple Myeloma 6.3 Brain Tumors 6.4 Lymphoma 6.5 Solid Tumors 7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase 7.1 Research 7.2 Preclinical 7.3 Clinical 7.4 Phase-I 7.5 Phase-I/II 7.6 Phase-II 7.7 Preregistration 8. Global Market Scenario of CAR T Cell Therapy 8.1 Overview 8.2 Estimated Price Analysis of CAR T Cell Therapy 9. Global Market Size of CAR T Cell Therapy 9.1 Market Share of Cancer Immunotherapy by its Technology 9.2 CAR T Cell Therapy Market Value 10. Global CAR T Cell Therapy Market Dynamics 10.1 Favorable Parameters 10.2 Challenges 11. Global CAR T Cell Therapy Market Future Prospects 12. Competitive Landscape 12.1 Autolus 12.2 Bellicum 12.3 Bluebird 12.4 Celgene 12.5 Cellectis 12.6 Celyad 12.7 Eureka Therapeutics 12.8 Fortress Biotech 12.9 Immune Therapeutics 12.10 Juno Therapeutics 12.11 Kite Pharma 12.12 Novartis 12.13 Sorrento therapeutics 12.14 TILT Biotherapeutics 12.15 Ziopharm For more information about this report visit http://www.researchandmarkets.com/research/6tj28w/global_car_t_cell


Patent
Sloan Kettering Cancer Center and Eureka Therapeutics | Date: 2017-10-11

The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.


Patent
Sloan Kettering Cancer Center and Eureka Therapeutics | Date: 2017-10-11

The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMC A- specific CARs have enhanced immune-activating properties, including anti-tumor activity.


Patent
Eureka Therapeutics and Sloan Kettering Cancer Center | Date: 2012-04-02

The present invention provides antigen binding proteins that specifically bind to Wilms tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.


Patent
Sloan Kettering Cancer Center and Eureka Therapeutics | Date: 2014-11-07

Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc* (NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis. Also provided are methods for stimulating a primary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen and a secondary T cell response comprising stimulating effector T cells and/or memory T cells against a first tumor antigen and/or against a second tumor antigen using the bi-specific antibodies described herein.


Patent
Sloan Kettering Cancer Center and Eureka Therapeutics | Date: 2015-05-28

The present invention provides antigen binding proteins that specifically bind to Wilms tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.


Patent
Sloan Kettering Cancer Center and Eureka Therapeutics | Date: 2014-11-07

The present disclosure relates to an anti-WT-1/HLA/A2 antibody with enhanced antibody dependent cell-mediated cytotoxicity (ADCC) function due to altered Fc glycosylation. The antibody, which has reduced fucose and/or galactose, was compared to its normally glycosylated counterpart in binding assays, in vitro ADCC assays, and mesothelioma and leukemia therapeutic models and pharmacokinetic studies in mice. The antibody with normal glycosylation mediated ADCC against hematopoietic and solid tumor cells at concentrations below 1 g/ml, but the reduced fucosylated antibody was about 5-10 fold more potent in vitro against multiple cancer cell lines, was more potent in vivo against JMN mesothelioma, and effective against SET2 AML and fresh ALL xenografts. ESKM had a shortened half-life (4.9 vs 6.5 days), but an identical biodistribution pattern in C57BL6/J mice. At therapeutic doses of ESKM, there was no difference in half-life or biodistribution in HLA-A2.1+ transgenic mice compared to the parent strain. Importantly, therapeutic doses of ESKM in these mice caused no depletion of total WBCs or hematopoietic stem cells, or pathologic tissue damage.

Loading Eureka Therapeutics collaborators
Loading Eureka Therapeutics collaborators